Skip to content
ContentLora

    Tip: press / anywhere to search.

    product

    Lenacapavir for HIV prevention

    Also known as Yeztugo, Yeytuo, LEN

    Lenacapavir is a long-acting injection given twice a year to prevent HIV, sold by Gilead as Yeztugo in the US and Yeytuo in the EU.[1][2][3] The FDA approved it for pre-exposure prophylaxis (PrEP) in June 2025, and WHO recommended it as an additional PrEP option on 14 July 2025.[2][4] In the PURPOSE 1 trial, none of the 2,134 young women given lenacapavir acquired HIV.[5]

    Editor reviewedStrict sourcingUpdated Wiki16 claims · 100% primaryInfectious disease, Health and medicine
    Key facts

    Lenacapavir is an HIV prevention medicine given as an injection twice a year.[1] Gilead sells it for pre-exposure prophylaxis (PrEP), medicine taken by HIV-negative people to lower their risk of infection, as Yeztugo in the US and Yeytuo in the EU.[2][3] WHO says the long-acting form may help with barriers to PrEP such as a daily pill, frequent clinic visits and stigma.[1] For background on the virus, see HIV explained.

    This page is not medical advice. Anyone considering PrEP should talk to a clinician or a sexual health service.

    Trial evidence

    The main evidence comes from randomised phase 3 trials. PURPOSE 1 was a double-blind trial among adolescent girls and young women in South Africa and Uganda.[5] None of the 2,134 participants given lenacapavir every 26 weeks acquired HIV. Infection rates were 2.02 per 100 person-years with daily oral F/TAF and 1.69 with daily oral F/TDF, against an estimated background rate of 2.41.[5] The trial noted that adherence to the daily pills was low.[6]

    PURPOSE 1 found no safety concerns. Injection-site reactions affected 68.8% of the lenacapavir group and 34.9% of those given placebo injections, and 0.2% of lenacapavir participants stopped treatment because of them.[6]

    Approvals and guidelines

    The FDA approved Yeztugo in June 2025 to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg. Gilead called it the first twice-yearly PrEP option in the US.[2] The European Commission authorised it as Yeytuo in the third quarter of 2025.[3] In the same quarter, Gilead said new CDC guidelines gave it a strong recommendation.[7]

    world-health-organization issued guidelines on 14 July 2025 recommending twice-yearly lenacapavir as an additional PrEP option.[4] The guidelines also recommended HIV rapid tests to support delivery of long-acting PrEP, so it can be offered through pharmacies, clinics and telehealth.[8] Other WHO-recommended options are daily oral PrEP, injectable cabotegravir and the dapivirine vaginal ring.[9] WHO reported 1.3 million new HIV infections worldwide in 2024.[10]

    Access in lower-income countries

    In 2025 Gilead agreed with the global-fund to supply lenacapavir PrEP for up to two million people over three years, mainly in low- and lower-middle-income countries, at no profit.[11] It announced a second partnership with the US State Department and PEPFAR, also for up to two million people over three years.[12]

    National approvals followed. Zambia authorised lenacapavir on 4 November 2025 after 12 working days, and Zimbabwe approved it after 18. Both relied on WHO’s Collaborative Registration Procedure, which used the EMA’s July 2025 assessment as its reference.[13] South Africa launched a national rollout in June 2026, starting in Secunda, Mpumalanga.[14]

    Sales and what comes next

    Gilead reported Yeztugo sales of $305 million in the third quarter of 2026, $294 million of it in the US.[15] A once-yearly lenacapavir injection was being tested in the phase 3 PURPOSE-365 trial as of October 2026 and is not approved.[16]

    More in Infectious disease

    Developing in Health

    Go deeper

    Questions readers ask

    What is lenacapavir for PrEP?

    A long-acting HIV prevention injection given twice a year. Gilead sells it as Yeztugo in the US and Yeytuo in the EU.[1][2][3]

    How well did lenacapavir work in trials?

    In PURPOSE 1, among 5,338 adolescent girls and young women in South Africa and Uganda, no one in the lenacapavir group acquired HIV. The comparison groups on daily pills had 1.69 and 2.02 infections per 100 person-years, and adherence to those pills was low.[5][6]

    What are the side effects?

    The PURPOSE 1 trial found no safety concerns. Injection-site reactions were common, affecting 68.8% of lenacapavir participants against 34.9% given placebo injections, and 0.2% stopped because of them.[6]

    Does WHO recommend lenacapavir?

    Yes. WHO guidelines issued on 14 July 2025 recommend twice-yearly injectable lenacapavir as an additional PrEP option, alongside daily oral PrEP, injectable cabotegravir and the dapivirine vaginal ring.[4][9]

    Is lenacapavir available in lower-income countries?

    Gilead agreed to supply it at no profit through the Global Fund for up to two million people over three years. Zambia and Zimbabwe approved it in late 2025, and South Africa began a national rollout in June 2026.[11][13][14]

    Is there a once-a-year version?

    A once-yearly injection was in the phase 3 PURPOSE-365 trial as of October 2026 and is not approved.[16]

    Sources

    · 16 claims from 3 publishers

    Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.

    1. [1]

      WHO describes lenacapavir as a long-acting injection given twice a year, which may help overcome barriers to PrEP such as the burden of a daily pill, frequent clinic visits and stigma. confirmedas of 2025-06-19

    2. [2]

      In June 2025 the FDA approved Gilead's twice-yearly injection Yeztugo (lenacapavir) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg. Gilead called it the first twice-yearly HIV PrEP option in the US. confirmedas of 2025-08-07

    3. [3]

      The European Commission granted marketing authorisation for lenacapavir PrEP, under the brand name Yeytuo, for adults and adolescents at increased risk of HIV-1, in the third quarter of 2025. confirmedas of 2025-10-30

    4. [4]

      On 14 July 2025, at the IAS 2025 conference in Kigali, WHO issued guidelines recommending twice-yearly injectable lenacapavir as an additional PrEP option for HIV prevention. confirmedas of 2025-07-14

    5. [5]

      In the phase 3 PURPOSE 1 trial among 5,338 adolescent girls and young women in South Africa and Uganda, none of the 2,134 participants given lenacapavir every 26 weeks acquired HIV, against 2.02 infections per 100 person-years with daily oral F/TAF, 1.69 with daily oral F/TDF and an estimated background incidence of 2.41. confirmedas of 2024-07-24

    6. [6]

      PURPOSE 1 found no safety concerns. Injection-site reactions were more common with lenacapavir (68.8%) than with placebo injections (34.9%), and 0.2% of lenacapavir participants stopped because of them. Adherence to the daily pills in the comparison groups was low. confirmedas of 2024-07-24

    7. [7]

      In the third quarter of 2025, new CDC guidelines gave a strong recommendation for twice-yearly injectable lenacapavir for HIV PrEP, according to Gilead. confirmedas of 2025-10-30

    8. [8]

      WHO's 2025 guidelines also recommended using HIV rapid tests to support delivery of long-acting injectable PrEP, so that it can be offered through pharmacies, clinics and telehealth. confirmedas of 2025-07-14

    9. [9]

      Other PrEP options recommended by WHO include daily oral PrEP, long-acting injectable cabotegravir and the dapivirine vaginal ring. confirmedas of 2025-07-14

    10. [10]

      WHO reported 1.3 million new HIV infections worldwide in 2024. confirmedas of 2025-07-14

    11. [11]

      In 2025 Gilead agreed with the Global Fund to supply twice-yearly lenacapavir PrEP for up to two million people over three years, mainly in low- and lower-middle-income countries, at no profit to Gilead, subject to regulatory approvals. confirmedas of 2025-08-07

    12. [12]

      Gilead also announced a partnership with the US State Department and PEPFAR to deliver lenacapavir PrEP for up to two million people over three years in countries supported by both PEPFAR and the Global Fund. confirmedas of 2025-10-30

    13. [13]

      Zambia's medicines regulator authorised lenacapavir for HIV prevention on 4 November 2025 after 12 working days of review, and Zimbabwe's regulator approved it after 18 working days, both using WHO's Collaborative Registration Procedure with the EMA's July 2025 EU-M4all assessment as the reference. confirmedas of 2025-12-01

    14. [14]

      In June 2026 South Africa launched a national rollout of twice-yearly injectable lenacapavir PrEP, starting in Secunda, Mpumalanga province. confirmedas of 2026-06-15

    15. [15]

      Gilead reported Yeztugo sales of $305 million in the third quarter of 2026, $294 million of it in the US, and $702 million in the first nine months of 2026. confirmedas of 2026-10-29

    16. [16]

      As of October 2026, Gilead was testing a once-yearly lenacapavir injection for HIV prevention in the phase 3 PURPOSE-365 trial; it is not approved. confirmedas of 2026-10-29

    Revision history (1)
    1. Page created.

    Created Nov 14, 2026. Last reviewed by an editor on Nov 15, 2026. Next scheduled review: Nov 14, 2027.

    Cite this page

    "Lenacapavir for HIV prevention." ContentLora, updated Nov 14, 2026. https://contentlora.com/wiki/lenacapavir-for-prep

    Spotted an error? Suggest a correction or emailcorrections@contentlora.com.